APC As a High-Utility Mutational Biomarker That May Identify Subpopulations of Patients with Mutant RAS/BRAF and Right-Sided Colorectal Cancer (CRC) Who Derive Benefit from EGFR Inhibitors (Egfri).
Journal of Clinical Oncology(2024)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要